Search
10X Genomics Inc
TXGAdd to Watchlist
35.730USD
+1.130+3.27%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
4.54BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.27%
5 Days
+2.81%
1 Month
+50.89%
6 Months
+114.08%
Year to Date
+119.07%
1 Year
+206.43%
Key Figures
34.660Open
36.880High
2.95MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.31%Turnover Ratio
34.600Prev. Close
34.610Low
78.50MTurnover
LossP/E Static
5.73P/B
0.00%Div Yield TTM
-2.36%ROA
28.17052wk High
0.80Volume Ratio
-182.63MNet Profit
127.69MShares
-0.1738EPS TTM
2.11Beta
-2.98%ROE
8.81052wk Low
6.56%Amplitude
70.39%Gross Margin
4.54BMarket Cap
8.82Reward/Risk
4.04%Risk Rate
TradingKey Stock Score of 10X Genomics Inc
Currency: USD Updated: 2026-06-25Key Insights
10X Genomics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 203 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 27.62.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
10X Genomics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
10X Genomics Inc Highlights
StrengthsRisks
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Undervalued
The company’s latest PE is -205.56, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 140.84M shares, decreasing 2.05% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 9.75M shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
27.615
Target Price
-13.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
10X Genomics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
10X Genomics Inc Info
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Ticker SymbolTXG
Company10X Genomics Inc
CEOSaxonov (Serge Wilson)
Websitehttps://www.10xgenomics.com/
Related Instruments
+2.48%
+2.79%
+3.08%
-0.53%
+2.39%
+2.80%
+0.84%
+0.51%
-0.20%
+0.93%
+0.93%
-0.57%
+0.87%
+0.11%
+4.77%
+3.92%
+1.05%
+2.49%
+2.97%
+0.30%Popular Instruments
51995.900
-28.800 (-0.06%)
29226.100
-228.900 (-0.78%)
7341.700
-25.100 (-0.34%)
15128.000
-623.000 (-3.96%)
69687.000
-1445.000 (-2.03%)
6243.800
-22.000 (-0.35%)
70.408
-0.936 (-1.31%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4028.020
+1.870 (+0.05%)
FAQs
What is the current price of 10X Genomics Inc (TXG)?
The current price of 10X Genomics Inc (TXG) is 35.73.
What is the symbol of 10X Genomics Inc?
The ticker symbol of 10X Genomics Inc is TXG.
What is the 52-week high of 10X Genomics Inc?
The 52-week high of 10X Genomics Inc is 28.17.
What is the 52-week low of 10X Genomics Inc?
The 52-week low of 10X Genomics Inc is 8.81.
What is the market capitalization of 10X Genomics Inc?
The market capitalization of 10X Genomics Inc is 4.56B.
Is 10X Genomics Inc (TXG) currently rated as Buy, Hold, or Sell?
According to analysts, 10X Genomics Inc (TXG) has an overall rating of Buy, with a price target of 27.62.
What is the Earnings Per Share (EPS TTM) of 10X Genomics Inc (TXG)?
The Earnings Per Share (EPS TTM) of 10X Genomics Inc (TXG) is -0.35.
